SCHEMBL7973315

SCHEMBL7973315

CC(C)C[AlH]CC(C)C.[AlH3]

nearest known ligand 0.31

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20240045 0.96
SCHEMBL27495780 0.96
Hydrochloric Acid SCHEMBL28965130 0.96
SCHEMBL4756218 0.96
Fluoride SCHEMBL28089853 0.96
SCHEMBL20972352 0.96 TSHR (0.33) TSHR
SCHEMBL333 0.96
SCHEMBL1252266 0.92 TSHR (0.31) TSHR
SCHEMBL22366993 0.92
Hydrochloric Acid SCHEMBL10748266 0.92 TSHR (0.31) TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3277695-B1 METHOD FOR PRODUCING METAL ORGANYLS ALBEMARLE GERMANY GMBH (DE) 2022-06-15 EP claimed
US-20180162880-A1 METHOD FOR PRODUCING METAL ORGANYLS ALBEMARLE GERMANY GMBH (DE) 2018-06-14 US claimed
EP-3943215-A1 METAL PASTE, BONDING METHOD AND METHOD FOR PRODUCING BONDED BODY Harima Chemicals, Inc. (JP) 2022-01-26 EP disclosed
EP-2810960-B1 POLYMERIZATION-CATALYST COMPOSITION FOR CONJUGATED-DIENE MONOMER ASAHI CHEMICAL IND (JP) 2017-08-09 EP disclosed
US-9556285-B2 Catalyst composition for polymerizing conjugated diene monomer ASAHI KASEI CHEMICALS CORPORATION (JP) 2017-01-31 US disclosed
US-20140378620-A1 CATALYST COMPOSITION FOR POLYMERIZING CONJUGATED DIENE MONOMER ASAHI KASEI CHEMICALS CORPORATION (JP) 2014-12-25 US disclosed
EP-2810960-A1 POLYMERIZATION-CATALYST COMPOSITION FOR CONJUGATED-DIENE MONOMER Asahi Kasei Chemicals Corporation (JP) 2014-12-10 EP disclosed
US-6277859-B1 HIGHLY SELECTIVE KAPPA-OPIOID AGONISTS USEFUL AS ANALGESICS AND DIURETICS WITH REDUCED PHYSIOLOGICAL SIDE EFFECTS TORAY INDUSTRIES, INC. (JP) 2001-08-21 US disclosed
EP-0577847-B1 MORPHINAN DERIVATIVE AND MEDICINAL USE TORAY INDUSTRIES (JP) 1998-10-14 EP disclosed
EP-0846694-A1 Morphinan derivative and its pharmaceutical applications TORAY INDUSTRIES, INC. (JP) 1998-06-10 EP disclosed
EP-0577847-A1 MORPHINAN DERIVATIVE AND MEDICINAL USE TORAY INDUSTRIES, INC. (JP) 1994-01-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162880-A1 METHOD FOR PRODUCING METAL ORGANYLS MRM1, HVCN1, PNN TSHR 3735/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.